WASHINGTON: India has reached out to American pharma companies seeking to invest in the country’s pharmaceutical and medical devices, in response to the second wave of the coronavirus epidemic.
Ambassador of India U.S. Taranjit Singh Sandhu No CEO has had virtual meetings with Alberta Borla Pfizer, Mark Thesper, CEO of Thermo Fisher, Chairman and CEO of Antilia Scientific, Bernd Burst, and Joseph Rap, CEO of Paul. Life Sciences.
He also had a phone call with Saitiva CEO and President Emanuel Ligner.
During talks with pharma companies, Sandhu said India wants to encourage investment in the pharmaceutical and medical devices sector.
He said India has recently launched a manufacturing-linked incentive scheme that will help the U.S. Will provide new investment opportunities to companies.
“Pfizer is discussing ways to support healthcare efforts in India, including vaccines, and to strengthen our response to the epidemic,” Sandhu said after a meeting with Borla last week.
On Monday, Borla said Pfizer follows with concern the serious COVID-19 situation in India and his company is making all possible efforts to provide support.
“Today we announced that we are mobilizing the largest humanitarian relief effort in the history of our company to help the people of India fight the vicious wave of coronavirus that is currently plaguing the country,” he said.
Among other things, it announced the donation of પૂર 70 million worth of medicines to every public hospital in India to ensure free access to every Covid-19 patient in the next 90 days.
The effort is likely to have an impact on the lives of hundreds of patients, Borla said.
In his meeting with Thermo Fisher CEO Mark Carper, Sandhu emphasized his important role in fighting the epidemic, including speeding up the supply of raw materials to India. Covishield Vaccines as well as essential drugs such as remedesivir.
Massachusetts-based Thermo Fisher is a key player in the supply chain for biopharma products. It provides analytical equipment, laboratory equipment, chemicals and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutes and government agencies.
During a meeting with Rap, CEO of Pall Life Sciences, the Indian Ambassador called for strengthening the supply chain, and expediting inputs for critical drugs such as remediation. Novav ax x The vaccine.
Pall biotech products have played a key role in life-saving drugs ranging from the Ebola vaccine to cancer-treating monoclonal antibodies. Given the current epidemic, its products have a huge relevance and are part of a critical supply chain in the industry.
The company has an extensive network in India, with offices in Mumbai, Ahmedabad, Hyderabad, Chandigarh, Delhi and Bangalore.
Sandhu praised his company’s efforts to ensure timely inputs for the Covishield and Novavex vaccines in his call with Antilia Scientific chairman and CEO Bernd Burst.
Antilia Scientific specializes in global peristaltic and single-use bioprocessing solutions, with a diverse portfolio of life sciences and diagnostic products for the pharma, biopharma, healthcare and environmental markets.
The Ambassador also worked with Emanuel Ligner, CEO and President of CTVA, a global provider of technologies and services that promote and accelerate therapeutic development and production.